Ionis Pharmaceuticals (NASDAQ: IONS) net income
Ionis Pharmaceuticals reported a net loss of $381.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $453.9m. Earnings per share were −$2.38.
Ionis Pharmaceuticals's best year of the last 10 was fiscal 2019. It reported a loss in 7 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$381.4m | — | −40.4% | −$2.38 |
| 2024 | −$453.9m | — | −64.4% | −$3.04 |
| 2023 | −$366.3m | — | −46.5% | −$2.56 |
| 2022 | −$269.7m | — | −45.9% | −$1.90 |
| 2021 | −$28.6m | — | −3.5% | −$0.20 |
| 2020 | −$444.3m | −259.7% | −60.9% | −$3.23 |
| 2019 | $278.1m | +1.6% | 24.8% | $2.00 |
| 2018 | $273.7m | +79,015.9% | 45.6% | $2.09 |
| 2017 | $0.3m | — | 0.1% | $0.15 |
| 2016 | −$60.4m | — | −16.2% | −$0.50 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Ionis Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Ionis Pharmaceuticals ranks 463rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Ionis Pharmaceuticals, −40.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 461st | Zenas BioPharma | −$377.7m | −3,777.4% |
| 462nd | Scholar Rock | −$377.9m | — |
| 463rd | Ionis Pharmaceuticals | −$381.4m | −40.4% |
| 464th | Iovance Biotherapeutics | −$391.0m | −148.4% |
| 465th | agilon health | −$391.3m | −6.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Ionis Pharmaceuticals
- How much did Ionis Pharmaceuticals earn in fiscal 2025?
- Ionis Pharmaceuticals reported a net loss of $381.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $453.9m.
- What are the earnings per share of Ionis Pharmaceuticals?
- They were −$2.38 in fiscal 2025, compared with −$3.04 in fiscal 2024.
- What was the most profitable year for Ionis Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2019, with $278.1m.
- Where does Ionis Pharmaceuticals rank in its sector by net income?
- It ranks 463rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Ionis Pharmaceuticals come from?
- From the annual report (Form 10-K) that Ionis Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Ionis Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Ionis Pharmaceuticals: the Ionis Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.